capitalizing, growth opportunities, complex generics, business models

Capitalizing On Growth Opportunities For Complex Generics To Strengthen Business Models

At the World Generic Medicines Congress Europe 2014, Dr Deepak Murpani, Synthon, gave the presentation “Capitalizing On Growth Opportunities For Complex Generics To Strengthen Business Models ” Download and learn: Why generics/ complex generics? Market trend What are complex generics? Case studies Summary Download presentation Found this interesting? Join us at the 9th annual World Generic Medicines Congress Europe, happening this 4-5 …

How to achieve performance and growth in an era of increased compliance

> Click here to download the presentation This presentation was delivered by Andrew Frye from DKSH at BioPharma Asia 2013. It focuses on how to achieve performance and growth via outsourcing in an era of increased compliance. The  presentation covers: DKSH – who we are? Achieving Growth – Commercial Capabilities Compliance and Sustainability – Trust and Visibility > Click here …

Growth of orphan drug market puts the World Orphan Drug Congress USA in the spotlight

Differently from the uncertainty of the economic growth across developed countries, the pharmaceutical industry is optimistic about the increasing revenue from orphan drug development. In a recent report conducted by BCC Research, the orphan drug market in 2012 was evaluated in $82 billion and is expected to grow at an average rate of 5.4% in the next five years, to …

eBook: 25 tips to nurture growth & opportunities in Asia’s emerging and developed markets

According to healthcare analysts at IMS Health, "Emerging markets will nearly double their spending on medicine over the next five years from $194bn in 2011 to $345-375bn in 2016."  The Global use of Medicines: Outlook through 2016, says the expected rise comes from a combination of increasing income levels, the increased affordability of medicines and the roll-out of government healthcare …

#CSL is a good bet according to the stock market

CSL has entered into the list of top 10 Australian businesses. CSL an Australian founded #biotech, floated in 1994 at $2.30 a share (equivalent to 77cents these days), and has risen up to 5000 per cent to around $37 per share. Shareholders have received dividends of $5 per share and that is not something that happened by accident. CSL enjoys …